RxDoctor Payments Data

Clifford Risk

Pulmonary Disease · Marlborough, MANPI 1013029651

Payments from drug & device makers

$8,726in general payments, 2019–2025

Across 421 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • GSK$992
  • Regeneron Healthcare Solutions, Inc.$772
  • Amgen$556
  • Sanofi$302
  • Electromed, Inc.$217
  • plus $466 from 10 others

What the payments were for

  • Food & beverage$8,00197%
  • Education$2253%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,726 in reported general payments places this provider in the 75th percentile of 482 pulmonary disease providers in Massachusetts.

See all pulmonary disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$134,317
Medicare patients
196
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TezspireTezepelumab-Ekko20$86,159
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$74,390
Dupixent PenDupilumab13$49,091
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$28,163
FarxigaDapagliflozin Propanediol19$26,555
OzempicSemaglutide21$22,063
EliquisApixaban17$16,581
TrulicityDulaglutide12$12,167
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,872
Combivent RespimatIpratropium/Albuterol Sulfate12$5,778
Fluticasone Propionate HfaFluticasone Propionate15$5,666
Breo ElliptaFluticasone/Vilanterol12$4,648
Advair HfaFluticasone Propion/Salmeterol11$4,368
AmbienZolpidem Tartrate11$4,314
Albuterol Sulfate HfaAlbuterol Sulfate104$3,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Farxiga$5,421$140,87674 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$992$84,910135 claims
PfizerEliquis$14$16,58117 claims
Sanofi-aventis U.S. LLCAmbien$21$4,31411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 482 pulmonary disease providers in Massachusetts.

Other pulmonary disease in Marlborough

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →